Breast Cancer

Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.

Officials with the FDA have approved ibalizumab-uiyk (Trogarzo, TaiMed Biologics), the first antiretroviral medication for adults with HIV who cannot be successfully treated with other therapies.

A new direct-to-consumer test analyzes saliva for 3 BRCA variants that may elevate the risk of various types of cancer.

A new direct-to-consumer test analyzes saliva for 3 BRCA variants that may elevate the risk of various types of cancer.

Top news of the week from Specialty Pharmacy Times.

The FDA previously approved abemaciclib for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy.

Newly-discovered gene mutations could double the risk of breast cancer.

Three genes may increase the risk of breast and ovarian cancers in patients with BRCA mutations.

Patients with a high risk of recurrent breast cancer may not receive chemotherapy.

The Maraba virus combined with an immune checkpoint inhibitor increased triple-negative breast cancer survival in mice.

Olaparib (Lynparza) is indicated to treat HER2-negative metastatic breast cancer with BRCA mutations.

Advancing biomarker research may help determine which patients with non-invasive breast cancer will develop invasive disease.

Conflicting breast cancer treatment guidelines can leave many decisions to the discretion of the provider.

Providing information about breast cancer surgery via an online tool may help patients feel more informed about their treatment options.

GammaPod system can accurately deliver radiation therapy to breast tumors.

Pembrolizumab plus trastuzumab may overcome drug-resistance among patients with advanced HER2+ breast cancer.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Patients treated with chemotherapy biweekly were 17% less likely to experience breast cancer recurrence over 10 years.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.

Mastectomy for early-stage breast cancer increases the risk of missing more than 1 month of work.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.